Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population

[1]  N. Gronich,et al.  Association Between Use of Pharmacokinetic‐Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case‐Control Study , 2021, Clinical pharmacology and therapeutics.

[2]  E. Chan,et al.  Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents. , 2021, Drug metabolism and pharmacokinetics.

[3]  Andy Z. X. Zhu,et al.  Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective , 2020, Clinical pharmacology and therapeutics.

[4]  K. Skov,et al.  Supratheraputic rivaroxaban levels: A persistent drug‐drug interaction after discontinuation of amiodarone , 2020, Basic & clinical pharmacology & toxicology.

[5]  E. Chan,et al.  Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban , 2019, Drug Metabolism and Disposition.

[6]  R. Reilly,et al.  Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[7]  Salik Nazir,et al.  A Rare Case of Spontaneous Cardiac Tamponade Induced by Concomitant Use of Rivaroxaban and Amiodarone , 2018, Case reports in cardiology.

[8]  E. Chan,et al.  Rivaroxaban With and Without Amiodarone in Renal Impairment. , 2018, Journal of the American College of Cardiology.

[9]  K. Giacomini,et al.  PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters , 2018, Clinical pharmacology and therapeutics.

[10]  Rohan M. Shah,et al.  Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice , 2017, Therapeutic advances in cardiovascular disease.

[11]  G. Venkatesan,et al.  Application of Static Modeling in the Prediction of In Vivo Drug–Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies , 2017, Drug Metabolism and Disposition.

[12]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[13]  J. Finsterer,et al.  Fatal intracerebral bleeding under rivaroxaban. , 2015, International journal of cardiology.

[14]  W. Mueck,et al.  Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban , 2013, Clinical Pharmacokinetics.

[15]  Ulrich Klotz,et al.  Pharmacokinetics and drug metabolism in the elderly , 2009, Drug metabolism reviews.